Applications of Microfluidic Devices for Urology

Han, Se Jik; Park, Hun-Kuk; Kim, Kyung Sook

doi:10.5213/inj.1734838.419

Cited by 17 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The on-chip manipulation of seminal fluid is mainly dedicated to the sorting and selection of cells suitable for in vitro fertilization procedures ( Marzano et al, 2019 ). Indeed, a remarkable number of devices, including passive and active microfluidics have been demonstrated to be able to select high motility from low motility sperm cells ( Cho et al, 2003 ), to sort chromosome X- or Y-loaded spermatozoa ( Koh and Marcos, 2015 ) or to count them ( Han et al, 2017 ). With respect to on-chip diagnosis of diseases, not directly related to sperm cells, none or very few examples are reported in literature.…”

Section: Liquid Biopsymentioning

confidence: 99%

Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics

Ferrara

Zoupanou

Primiceri

et al. 2022

Biosensors and Bioelectronics

View full text Add to dashboard Cite

Liquid biopsy technologies have seen a significant improvement in the last decade, offering the possibility of reliable analysis and diagnosis from several biological fluids. The use of these technologies can overcome the limits of standard clinical methods, related to invasiveness and poor patient compliance. Along with this there are now mature examples of lab-on-chips (LOC) which are available and could be an emerging and breakthrough technology for the present and near-future clinical demands that provide sample treatment, reagent addition and analysis in a sample-in/answer-out approach. The possibility of combining non-invasive liquid biopsy and LOC technologies could greatly assist in the current need for minimizing exposure and transmission risks. The recent and ongoing pandemic outbreak of SARS-CoV-2, indeed, has heavily influenced all aspects of life worldwide. Ordinary tasks have been forced to switch from “in presence” to “distanced”, limiting the possibilities for a large number of activities in all fields of life outside of the home. Unfortunately, one of the settings in which physical distancing has assumed noteworthy consequences is the screening, diagnosis and follow-up of diseases. In this review, we analyse biological fluids that are easily collected without the intervention of specialized personnel and the possibility that they may be used -or not-for innovative diagnostic assays. We consider their advantages and limitations, mainly due to stability and storage and their integration into Point-of-Care diagnostics, demonstrating that technologies in some cases are mature enough to meet current clinical needs.

show abstract

Section: Liquid Biopsymentioning

confidence: 99%

Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics

Ferrara

Zoupanou

Primiceri

et al. 2022

Biosensors and Bioelectronics

View full text Add to dashboard Cite

show abstract

“…Over the last two decades, the process illustrated in Fig. 1 has been a method of choice for fabricating various microfluidic devices that target numerous applications, both in continuous and two-phase microfluidics [10][11][12].…”

Section: Conventional Soft Lithographymentioning

confidence: 99%

A Novel Method for Fabricating Microfluidic Devices Containing Immobilized Biological Specimens

Hamidović

Ender

2019

Period. Polytech. Elec. Eng. Comp. Sci.

View full text Add to dashboard Cite

Microfluidic devices are dominantly fabricated using the soft lithography microfabrication techniques and polydimethylsiloxane (PDMS) as a structural material. Although the technique is applicable for the majority of microfluidic devices, it has limited use for the fabrication of microfluidic devices with immobilized biological specimen due to the low biocompatibility- a consequence of the plasma-assisted bonding step during the assembly of the final device. In this step, biological specimens within the microfluidic device are affected by strong plasma exposure which ultimately can degrade their biochemical activity and stability. To the best of our knowledge, this paper presents for the first time a method for increasing the biocompatibility of a conventional PDMS soft lithography process and enables fabrication of the microfluidic devices containing immobilized biological specimens. Protection of the biological specimen during the plasma bonding step is ensured by placing a protective Polyvinyl Alcohol (PVA) nanofiber layer over the biological specimens. The method is verified against the conventional soft lithography method by fabricating microfluidic devices containing enzyme-filled microreactors and following enzymatic reactions. It was shown that inadvantageous impact of the plasma is reduced by utilizing a protective PVA layer which ultimately preserves the specific activity and biochemical stability of the immobilized enzymes.

show abstract

“…Due to their high throughput and low cost, microfluidic-based diagnostic tools hold the promise for improved patient care and outcomes considering the limitations of current screening and diagnostic techniques as well as the societal and economic impact of BC ( 22 , 23 ). Microfluidics enables precise manipulation of biological samples and can potentially provide portability and automation, offering exceptional advantages for clinical application ( 24 ).…”

Section: Introductionmentioning

confidence: 99%

Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies

et al. 2020

View full text Add to dashboard Cite

Bladder cancer is the most common malignancy of the urinary tract, having one of the highest recurrence rates and progression from non-muscle to muscle invasive bladder cancer that commonly leads to metastasis. Cystoscopy and urine cytology are the standard procedures for its detection but have limited clinical sensitivity and specificity. Herein, a microfluidic device, the UriChip, was developed for the enrichment of urothelial exfoliated cells from fresh and frozen urine, based on deformability and size, and the cancer-associated glycan Sialyl-Tn explored as a putative bladder cancer urinary biomarker. Spiking experiments with bladder cancer cell lines showed an isolation efficiency of 53%, while clinical sample analyses revealed retention of cells with various morphologies and sizes. in situ immunoassays demonstrated significantly higher number of Sialyl-Tn-positive cells in fresh and frozen voided urine from bladder cancer patients, compared to healthy individuals. Of note, urothelial exfoliated cells from cryopreserved urine sediments were also successfully isolated by the UriChip, and found to express significantly high levels of Sialyl-Tn. Remarkably, Sialyl-Tn expression is correlated with tumor stage and grade. Overall, our findings demonstrate the potential of UriChip and Sialyl-Tn to detect urothelial bladder cancer cells in follow-up and long-term retrospective studies.

show abstract

Applications of Microfluidic Devices for Urology

Cited by 17 publications

References 32 publications

Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics

Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics

A Novel Method for Fabricating Microfluidic Devices Containing Immobilized Biological Specimens

Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies

Contact Info

Product

Resources

About